[HTML][HTML] Improved survival with MEK inhibition in BRAF-mutated melanoma
…, B Dreno, M Nyakas, MR Middleton… - … England Journal of …, 2012 - Mass Medical Soc
Background Activating mutations in serine–threonine protein kinase B-RAF (BRAF) are found
in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves …
in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves …
Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A
…, I Karydis, M Jones, R Asher, M Salio, M Middleton… - Nature …, 2010 - nature.com
Neutrophils are the main effector cells during inflammation, but they can also control
excessive inflammatory responses by secreting anti-inflammatory cytokines. However, the …
excessive inflammatory responses by secreting anti-inflammatory cytokines. However, the …
[HTML][HTML] Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines
…, M Haedersdal, J Malvehy, MR Middleton… - European Journal of …, 2019 - Elsevier
Basal cell carcinoma (BCC) is the most common malignant tumour in white populations.
Multidisciplinary experts from the European Dermatology Forum, the European Association of …
Multidisciplinary experts from the European Dermatology Forum, the European Association of …
[HTML][HTML] Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
…, JJ Grob, MO Butler, MR Middleton… - … England Journal of …, 2017 - Mass Medical Soc
Background Nivolumab and ipilimumab are immune checkpoint inhibitors that have been
approved for the treatment of advanced melanoma. In the United States, ipilimumab has also …
approved for the treatment of advanced melanoma. In the United States, ipilimumab has also …
[HTML][HTML] Talimogene laherparepvec improves durable response rate in patients with advanced melanoma
…, GA Daniels, K Harrington, MR Middleton… - Journal of clinical …, 2015 - iro.uiowa.edu
Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-derived oncolytic
immunotherapy designed to selectively replicate within tumors and produce granulocyte …
immunotherapy designed to selectively replicate within tumors and produce granulocyte …
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma …
…, RM Charnley, F Lacaine, AG Scarfe, MR Middleton… - Jama, 2012 - jamanetwork.com
Context Patients with periampullary adenocarcinomas undergo the same resectional
surgery as that of patients with pancreatic ductal adenocarcinoma. Although adjuvant …
surgery as that of patients with pancreatic ductal adenocarcinoma. Although adjuvant …
[HTML][HTML] Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline
Cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in Caucasian
populations, accounting for 20% of all cutaneous malignancies. A unique collaboration …
populations, accounting for 20% of all cutaneous malignancies. A unique collaboration …
[HTML][HTML] Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline–Update 2016
…, K Peris, A Hauschild, P Saiag, M Middleton… - European journal of …, 2016 - Elsevier
Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumour and causes
90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts from the …
90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts from the …
Phase I study of the poly (ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors
R Plummer, C Jones, M Middleton, R Wilson… - Clinical cancer …, 2008 - AACR
Purpose: One mechanism of tumor resistance to cytotoxic therapy is repair of damaged DNA.
Poly(ADP-ribose) polymerase (PARP)-1 is a nuclear enzyme involved in base excision …
Poly(ADP-ribose) polymerase (PARP)-1 is a nuclear enzyme involved in base excision …
[PDF][PDF] Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 …
…, G Butturini, PA Lind, MR Middleton… - Journal of clinical …, 2014 - openaccessrepository.it
… Certain relationships marked with a “U” are those for which no compensation was
received; those relationships marked with a “C” were compensated. For a detailed …
received; those relationships marked with a “C” were compensated. For a detailed …